Eyal C. Attar - 25 Aug 2021 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Role
SVP, Chief Medical Officer
Signature
/s/ Scott M. Coiante, attorney-in-fact
Issuer symbol
APRE
Transactions as of
25 Aug 2021
Transactions value $
-$35,947
Form type
4
Filing time
27 Aug 2021, 17:00:50 UTC
Next filing
20 Sep 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APRE Common Stock Tax liability -$35.9K -9.03K -8.36% $3.98 99K 25 Aug 2021 Direct F1
holding APRE Common Stock 172 25 Aug 2021 By adult child F2
holding APRE Common Stock 159 25 Aug 2021 By child F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of 25,000 restricted stock units
F2 Net of 28 shares sold by account custodian to satisfy account minimum. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.
F3 Net of 41 shares sold by account custodian to satisfy account minimum. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.